Many of the directions included in the order will be familiar to those who watched drug pricing policy closely during the ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers. Over the course of March, the U.S. Food and Drug Administration ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Cytisinicline increased biochemically confirmed abstinence nearly threefold versus placebo when taken for 6 weeks and more than fourfold when taken for 12 weeks. The drug was well tolerated with ...

A bill signed into law by Gov. Mike Braun on Tuesday expands the kinds of opioid reversing medications that can be stocked in ...

Healthpeak Properties, Inc. ( NYSE: DOC) Q1 2025 Earnings Conference Call April 25, 2025 10:00 AM ET Andrew Johns - Senior Vice President, IR Scott Brinker - President and CEO Kelvin Moses - Chief ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

FDA grants orphan drug designation to HLX22 for gastric cancer ... compared with 8.3 months in the placebo arm. The 12-month PFS rates were 73.8% and 34.2%, respectively, and the 24-month PFS rates ...

Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the ...

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug ...

The International (CCHR), a leading mental health industry watchdog, has released a damning report detailing how ...